Faruqi & Faruqi, LLP Announces the Investigation of KYTHERA Biopharmaceuticals, Inc. (KYTH) Over the Proposed Sale of the Company to Allergan plc.
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of KYTHERA Biopharmaceuticals, Inc. (“Kythera” or the “Company”) (NasdaqGS: KYTH) for potential breaches of fiduciary duties in connection with the sale of the Company to Allergan plc. for approximately $2.1 billion. The Company’s stockholders will only receive approximately $75 per share for each share of Kythera common stock they own. The fixed-value transaction consideration will be payable 80 percent in cash and 20 percent in new Allergan shares issued to Kythera shareholders. However, at least one analyst has set a price target of $85.00 for shares of the Company.
If you own common stock in Kythera and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.